Palbociclib in Treating Patients With Relapsed or Refractory Rb Positive Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating Alterations in Cell Cycle Genes (A Pediatric MATCH Treatment Trial)

Inclusion Criteria:

• Patient must have enrolled onto APEC1621SC and must have been given a treatmentassignment to MATCH to APEC1621I based on the presence of an actionable mutation asdefined in APEC1621SC

• In addition to the actionable mutations, positive Rb expression byimmunohistochemistry is required for study enrollment

• Patients must be >= than 12 months and =< 21 years of age at the time of studyenrollment

• Patients must have a body surface area >= 0.87 m^2 at enrollment

• Patients must have radiographically measurable disease at the time of studyenrollment; patients with neuroblastoma who do not have measurable disease but haveMIBG+ evaluable disease are eligible; measurable disease in patients with CNSinvolvement is defined as any lesion that is at minimum 10 mm in one dimension onstandard magnetic resonance imaging (MRI) or computed tomography (CT).

• Note: The following do not qualify as measurable disease:

• Malignant fluid collections (e.g., ascites, pleural effusions)

• Bone marrow infiltration except that detected by MIBG scan forneuroblastoma

• Lesions only detected by nuclear medicine studies (e.g., bone, gallium orpositron emission tomography [PET] scans) except as noted forneuroblastoma

• Elevated tumor markers in plasma or cerebrospinal fluid (CSF)

• Previously radiated lesions that have not demonstrated clear progressionpost radiation

• Leptomeningeal lesions that do not meet the measurement requirements forResponse Evaluation Criteria in Solid Tumors (RECIST) 1.1

• Karnofsky >= 50% for patients > 16 years of age and Lansky >= 50 for patients =< 16years of age; Note: Neurologic deficits in patients with CNS tumors must have beenrelatively stable for at least 7 days prior to study enrollment; patients who areunable to walk because of paralysis, but who are up in a wheelchair, will beconsidered ambulatory for the purpose of assessing the performance score

• Patients must have fully recovered from the acute toxic effects of all prioranti-cancer therapy and must meet the following minimum duration from prioranti-cancer directed therapy prior to enrollment; if after the required timeframe,the numerical eligibility criteria are met, e.g. blood count criteria, the patientis considered to have recovered adequately

• Cytotoxic chemotherapy or other anti-cancer agents known to bemyelosuppressive; for agents not listed, the duration of this interval must bediscussed with the study chair and the study-assigned research coordinatorprior to enrollment

• >= 21 days after the last dose of cytotoxic or myelosuppressivechemotherapy (42 days if prior nitrosourea)

• Anti-cancer agents not known to be myelosuppressive (e.g. not associated withreduced platelet or absolute neutrophil counts [ANC] counts): >= 7 days afterthe last dose of agent

• Antibodies: >= 21 days must have elapsed from infusion of last dose ofantibody, and toxicity related to prior antibody therapy must be recovered tograde =< 1

• Corticosteroids: If used to modify immune adverse events related to priortherapy, >= 14 days must have elapsed since last dose of corticosteroid

• Hematopoietic growth factors: >= 14 days after the last dose of a long-actinggrowth factor (e.g. pegfilgrastim) or 7 days for short-acting growth factor;for growth factors that have known adverse events occurring beyond 7 days afteradministration, this period must be extended beyond the time during whichadverse events are known to occur; the duration of this interval must bediscussed with the study chair and the study-assigned research coordinator

• Interleukins, interferons and cytokines (other than hematopoietic growthfactors): >= 21 days after the completion of interleukins, interferon orcytokines (other than hematopoietic growth factors)

• Stem cell infusions (with or without total body irradiation [TBI]):

• Allogeneic (non-autologous) bone marrow or stem cell transplant, or anystem cell infusion including donor lymphocyte infusion (DLI) or boostinfusion: >= 84 days after infusion and no evidence of graft versus hostdisease (GVHD)

• Autologous stem cell infusion including boost infusion: >= 42 days

• Cellular therapy: >= 42 days after the completion of any type of cellulartherapy (e.g. modified T cells, natural killer [NK] cells, dendritic cells,etc.)

• Radiation therapy (XRT)/external beam irradiation including protons: >= 14 daysafter local XRT; >= 150 days after TBI, craniospinal XRT or if radiation to >= 50% of the pelvis; >= 42 days if other substantial bone morrow (BM) radiation

• Note: Radiation may not be delivered to "measurable disease" tumor site(s)being used to follow response to subprotocol treatment

• Radiopharmaceutical therapy (e.g., radiolabeled antibody, 131I-MIBG): >= 42days after systemically administered radiopharmaceutical therapy

• Patients must not have received prior exposure to palbociclib, ribociclib,abemaciclib or any other CDK4/6 inhibitors

• For patients with solid tumors without known bone marrow involvement:

• Peripheral absolute neutrophil count (ANC) >= 1000/mm^3

• Platelet count >= 100,000/mm^3 (transfusion independent, defined as notreceiving platelet transfusions for at least 7 days prior to enrollment)

• Patients with known bone marrow metastatic disease will be eligible for studyprovided they meet the blood counts (may receive transfusions provided they are notknown to be refractory to red cell or platelet transfusions); these patients willnot be evaluable for hematologic toxicity

• Creatinine clearance or radioisotope glomerular filtration rate (GFR) >= 70ml/min/1.73 m^2 or a serum creatinine based on age/gender as follows:

• Age: 1 to < 2 years; maximum serum creatinine (mg/dL): male 0.6; female 0.6

• Age: 2 to < 6 years; maximum serum creatinine (mg/dL): male 0.8; female 0.8

• Age: 6 to < 10 years; maximum serum creatinine (mg/dL): male 1; female 1

• Age: 10 to < 13 years; maximum serum creatinine (mg/dL): male 1.2; female 1.2

• Age: 13 to < 16 years; maximum serum creatinine (mg/dL): male 1.5; female 1.4

• Age: >= 16 years; maximum serum creatinine (mg/dL): male 1.7; female 1.4

• Bilirubin (sum of conjugated + unconjugated) =< 1.5 x upper limit of normal (ULN)for age

• Serum glutamate pyruvate transaminase (SGPT) (alanine aminotransferase [ALT]) =< 135U/L; (for the purpose of this study, the ULN for SGPT is 45 U/L)

• Serum albumin >= 2 g/dL

• Patients must be able to swallow intact capsules

• All patients and/or their parents or legally authorized representatives must sign awritten informed consent; assent, when appropriate, will be obtained according toinstitutional guidelines

Exclusion Criteria:

• Pregnant or breast-feeding women will not be entered on this study due to risks offetal and teratogenic adverse events as seen in animal/human studies; pregnancytests must be obtained in girls who are post-menarchal; males or females ofreproductive potential may not participate unless they have agreed to use aneffective contraceptive method for the duration of study treatment; females studyparticipants of child-bearing potential and their partners, should agree to usehighly effective forms of contraception for at least 3 weeks after the last dose ofpalbociclib; male study participants should avoid fathering a child, donating sperm,and should agree to use highly effective forms of contraception for at least 3months after the last dose of palbociclib

• Concomitant medications

• Corticosteroids: Patients receiving corticosteroids who have not been on astable or decreasing dose of corticosteroid for at least 7 days prior toenrollment are not eligible; if used to modify immune adverse events related toprior therapy, >= 14 days must have elapsed since last dose of corticosteroid

• Investigational drugs: Patients who are currently receiving anotherinvestigational drug are not eligible

• Anti-cancer agents: Patients who are currently receiving other anti-canceragents are not eligible

• Anti-GVHD agents post-transplant: Patients who are receiving cyclosporine,tacrolimus or other agents to prevent graft-versus-host disease post bonemarrow transplant are not eligible for this trial

• CYP3A4 agents: Patients who are currently receiving drugs that are stronginducers or inhibitors of CYP3A4 are not eligible; strong inducers orinhibitors of CYP3A4 should be avoided from 14 days prior to enrollment to theend of the study; Note: CYP3A4 inducing anti-epileptic drugs and dexamethasonefor CNS tumors or metastases, on a stable dose, are allowed

• Patients who have an uncontrolled infection are not eligible

• Patients who have received a prior solid organ transplantation are not eligible

• Patients who in the opinion of the investigator may not be able to comply with thesafety monitoring requirements of the study are not eligible